Fluorescent Evaluation of Colorectal Anastamoses

NCT ID: NCT01424293

Last Updated: 2021-07-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2016-09-30

Brief Summary

Bowel removal is indicated for various types of colon and rectal disease, including colon cancer, rectal cancer, diverticulitis, and inflammatory bowel disease among others.

Following removal of the diseased segment of bowel your surgeon will reconnect the two healthy ends to reconstruct a continuous bowel tube. If the bowel leaks it can become an extremely dangerous situation.

The cause of leakage has many causes and is not well understood, but appears to be at least in part due to not having enough blood going to the bowel. There is currently no way to evaluate the blood supply to the bowel.

The purpose of this study is to utilize a special camera to evaluate the blood supply of the bowel. This new system is called the Spy-scope. This system may assist surgeons in reducing the occurrence of leaks

Detailed Description

The purpose of this study is to evaluate whether systemically injected ICG, when fluorescing in response to NIR illumination, can assist with the assessment of perfusion at a bowel anastomotic site. This finding may assist surgeons to minimize the occurrence of leaks at the anastomotic site following this surgical procedure. The present study is a preliminary investigation to determine if this imaging modality will yield information regarding perfusion that is likely to be clinically relevant and so determine if a larger, multi center trial that correlates perfusion to clinical outcome is warranted. The results of the present study will also assist in the design of a larger scale study. It is expected that a successful outcome to such a trial will result in less morbidity following laparoscopic colectomy.

Laparoscopic bowel surgery is indicated for colon cancer, rectal cancer, diverticulitis, inflammatory bowel disease (including ulcerative colitis or Crohn's disease) and infarcted bowel. Prophylactic colectomy is also indicated for certain forms of polyposis to mitigate the risk of progression to colon cancer. The portion of colon resected during a colectomy is dependent upon the nature of the disease and its location and extent. Traditionally, colectomy has been performed by means of laparotomy, a standard abdominal incision. In recent years, beginning in the early 1990s, there has been increasing interest in, and utilization of, minimally invasive techniques for surgical procedures involving the colon and rectum. Laparoscopic surgery involves the introduction of surgical instruments through a number (usually 2-3) of small incisions measuring about 10-12 mm each with visual guidance being provided by means of a camera attached to an endoscope introduced through a similarly small access port. Laparoscopic techniques offer numerous benefits including a decrease in postoperative pain, some improvement in time to tolerance of food and return of bowel function, shorter hospital stay and more rapid return to normal activity.

Irrespective of the type of procedure performed (open or laparoscopic), anastomotic leakage following colorectal resection and primary anastomosis is a major clinical problem. The incidence of intraperitoneal anastomotic leaks reported in the literature may be as high as 30%. Anastomotic leaks leads to increased length of hospital stay, and may progress to abscess formation, sepsis, multi organ failure and even death.

The cause of anastomotic leakage is multifactorial with the following factors appearing to impact upon leakage; adequacy of blood flow to the anastomosis, contamination, the presence of a pelvic drain, anastomotic tension, anastomotic technique and the distance from the anal verge . The present study will investigate the first factor listed above, adequacy of blood flow to the anastomosis. At present there is no reliable and easy-to-perform modality that can be used to assess adequacy of perfusion at the anastomosis during colorectal procedures. This study will investigate the potential for the SPY scope to fill this clinical need.

The SPY® Intraoperative Imaging System is cleared for use in Canada, Japan, Europe and the US. SPY was originally developed for applications in cardiac surgery and allows cardiac surgeons to visually assess bypass graft quality in real-time while the patient is still in the operating room. Subsequently, SPY has received clearance from the FDA for use in plastic and reconstructive surgery and in solid organ transplant.

The SPY Intraoperative Imaging System was originally developed for open surgical procedures using ICG, which is an approved drug. ICG is a fluorescent compound, which can be administered intravenously or intra-arterially. The dye absorbs light in the near infrared (NIR) region at 806 nm, and emits light at a slightly longer wavelength, 830 nm. When injected intravenously, ICG rapidly and extensively binds to plasma proteins and is confined to the intravascular compartment with minimal leakage into the interstitium under normal conditions. This property makes it an ideal agent for the acquisition of high quality images of the vasculature. Intraoperative images are acquired during the first pass of a bolus of ICG through the area of interest. The SPY System has been the subject of numerous peer reviewed publications demonstrating its safety and efficacy .

SPY scope, the endoscopic version of SPY, is an endoscopic visible (VIS) NIR imaging system consisting of:

• An endoscopic light source that provides illumination for visible light imaging and NIR fluorescence excitation to the endoscope via a flexible light guide
• Rigid endoscopes optimized for illuminating the field of view and transmitting images in the visible and NIR spectrum, and
• A high definition (HD) endoscopic camera system connected to the endoscope eyepiece and acquiring high resolution visible and NIR fluorescence images The ICG (25 mg per vial) will be reconstituted according to the manufacturer's instructions using the entire contents (10 ml) of the sterile diluent supplied, yielding a 2.5 mg/ml solution of ICG or using half of the diluent supplied (5 ml) yielding a 5 mg/ml solution.

Conditions

Rectal Neoplasms; Colon Neoplasms; Diverticulitis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Indocyanine Green

1ml of intravenous ICG and imaging transanally using the Spyscope system

Group Type: EXPERIMENTAL

Indocyanine Green

Intervention Type: DEVICE

1ml of intravenous ICG and imaging transanally using the Spyscope system

The SPY® Intraoperative Imaging System

Intervention Type: DEVICE

Interventions

Indocyanine Green

1ml of intravenous ICG and imaging transanally using the Spyscope system

Intervention Type: DEVICE

The SPY® Intraoperative Imaging System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subject is willing and able to provide an informed consent
• Subject is willing and able to comply with the study procedures
• Subject speaks English and is able to understand the study procedures
• A pregnancy test for women of childbearing potential prior to surgery
• Subject is scheduled for laparoscopic low anterior resection

Exclusion Criteria

• Candidates for this study who meet any of the following criteria at the time of the baseline visit are NOT eligible to be enrolled in this study:

• Subject has uremia, serum creatinine >2.5 mg/dl
• Subject has a previous history of adverse reaction or allergy to ICG, iodine, shellfish or iodine dyes
• Subjects in whom the use of x-ray dye or ICG is contraindicated including development of adverse events when previously or presently administered
• Subject has any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure
• Subject is a pregnant or lactating female
• Subject is actively participating in another drug, biologic and/or device protocol

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Maimonides Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Danny A Sherwinter

Attending Physician, Surgery

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Danny Sherwinter, MD

Role: PRINCIPAL_INVESTIGATOR

Maimonides Medical Center

Locations

Maimonides Medical Center

Brooklyn, New York, United States

Countries

United States

Other Identifiers

1004va09

Identifier Type: -

Identifier Source: org_study_id